KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
10 Settembre 2024 - 1:00PM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced
that its management will participate in a fireside chat at the 2024
Cantor Global Healthcare Conference on Thursday, September 19th,
2024 at 10:20 a.m. ET in New York, N.Y.
A live webcast of the presentation will be available on the
Company’s website at www.kalvista.com. An audio archive will be
available on KalVista’s website for 30 days following the
presentation.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical
company focused on the development and delivery of oral medicines
for diseases with significant unmet need. KalVista announced
positive phase 3 data from the KONFIDENT trial for its oral,
on-demand therapy, sebetralstat for HAE in February 2024. The
Company’s NDA for sebetralstat has been accepted by the FDA with a
PDUFA goal date of June 17, 2025. KalVista received validation of
its MAA from the EMA in August 2024. KalVista expects to file for
approval in the UK, Japan, and other countries later in 2024.
For more information about KalVista, please visit
www.kalvista.com or follow on social media at
@KalVista and LinkedIn.
Forward-Looking Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, timing or
outcomes of communications with the FDA, our expectations about
safety and efficacy of our product candidates and timing of
clinical trials and its results, our ability to commence clinical
studies or complete ongoing clinical studies, including our
KONFIDENT-S and KONFIDENT-KID trials, and to obtain regulatory
approvals for sebetralstat and other candidates in development, the
success of any efforts to commercialize sebetralstat, the ability
of sebetralstat and other candidates in development to treat HAE or
other diseases, and the future progress and potential success of
our oral Factor XIIa program. Further information on potential risk
factors that could affect our business and financial results are
detailed in our filings with the Securities and Exchange
Commission, including in our annual report on Form 10-K for the
year ended April 30, 2024, our quarterly reports on Form 10-Q, and
our other reports that we may make from time to time with the
Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910918385/en/
Media: Jenn Snyder Vice President, Corporate Affairs
(857) 356-0479 jennifer.snyder@kalvista.com
Investors: Ryan Baker Head, Investor Relations (617)
771-5001 ryan.baker@kalvista.com
Grafico Azioni KalVista Pharmaceuticals (NASDAQ:KALV)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni KalVista Pharmaceuticals (NASDAQ:KALV)
Storico
Da Dic 2023 a Dic 2024
